Screener Summaries Updates Institutions Sign In More Updates › Other Events › CANF Other Events · Jul 14, 2026
On July 14, 2026, Can-Fite BioPharma Ltd. announced it has secured an Australian patent allowance to support the… CANF Can-Fite BioPharma Ltd.
On July 14, 2026, Can-Fite BioPharma Ltd. announced it has secured an Australian patent allowance to support the development and marketing of Namodenoson for the treatment of liver and pancreatic cancer. Can-Fite BioPharma Ltd. is a biotechnology company focused on developing therapeutic products.
More from Can-Fite BioPharma Ltd. EAPO allows patent for Piclidenoson in Lowe syndrome, strengthening IP foundation Nov 2, 2026 Presents final positive Phase IIa data for namodenoson in pancreatic cancer, achieving primary safety endpoint Oct 26, 2026 Can-Fite BioPharma Ltd. reported H1 2026 financial results showing a net loss of $4.6 million, compared to $4.87… Sep 8, 2026 On September 2, 2026, Can-Fite Biopharma Ltd. entered into an inducement offer letter with a warrant holder to… Sep 3, 2026 Can-Fite BioPharma Ltd. announced the exercise of outstanding warrants for approximately $4.0 million in gross… Sep 2, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
